Recurrent Transient Asymptomatic Pulmonary Opacity with Long-Term Afatinib: A Case Report

Afatinib is the second generation EGFR-TKI. Recently, transient asymptomatic pulmonary opacity (TAPO) was reported in EGFR-mutation harboring NSCLC receiving osimertinib. However, TAPO related to other EGFR-TKI has not been reported. Here, we reported a case of TAPO related to afatinib in lung adeno...

Descripción completa

Detalles Bibliográficos
Autores principales: Watanabe, Keisuke, Kobayashi, Nobuaki, Kaneko, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051041/
https://www.ncbi.nlm.nih.gov/pubmed/37008833
http://dx.doi.org/10.1159/000529894

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10051041/
https://www.ncbi.nlm.nih.gov/pubmed/37008833
http://dx.doi.org/10.1159/000529894

Ejemplares similares